Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic
Chemotherapy (PLOF) in resectable locally advanced gastric cancer.